To treat AGC, several ICIs, including pembrolizumab, avelumab, sintilimab, tislelizumab, and ipilimumab, have been given clinical approval.10,12-14 Tumor cells can avoid detection and clearance by the host immune system by suppressing T-cell immune reactions by activating ICIs like CTLA-4 and PD-1.15-18 For several cancers, ICIs have received approval, and combination therapy using ICI agents has become a new therapeutic option for advanced malignancies.19 This evidence concerns the gene CTLA4 and cancer.